Literature DB >> 22704920

Diagnosis and long-term course of Dravet syndrome.

Ingrid E Scheffer1.   

Abstract

Dravet syndrome is a severe infantile-onset epilepsy syndrome with a distinctive but complex electroclinical presentation. A healthy, developmentally normal infant presents at around 6 months of age with convulsive status epilepticus, which may be hemiclonic or generalized; seizures may be triggered by fever, illness or vaccination. The infant typically has further episodes of status epilepticus every month or two, often triggered by fever. Other seizure types including focal dyscognitive seizures, absence and myoclonic seizures develop between 1 and 4 years. Atonic drop attacks and episodes of non-convulsive status may occur. Early development is normal but slows in the second year. Developmental regression may occur, particularly with status epilepticus. EEG studies are initially normal, but after 2 years they show generalized spike-wave and polyspike-wave activity with multifocal discharges. Photosensitivity may be seen. Imaging is normal or shows non-specific findings such as atrophy. Dravet syndrome is associated with mutations of the gene encoding the alpha-1 subunit of the sodium channel, SCN1A, in >70% of patients. These include sequencing mutations and copy number variant anomalies; 90% of mutations arise de novo. PCDH19 mutational analysis is a second-tier test for girls with a Dravet-like picture who do not have SCN1A mutations. Outcome is poor, with intellectual disability in most patients and ongoing seizures. Intellectual impairment varies from severe in 50% patients, to moderate and mild intellectual disability each accounting for 25% cases. Rare patients have normal intellect. The long-term course involves ongoing, brief nocturnal convulsions and a characteristic deterioration in gait.
Copyright © 2012 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704920     DOI: 10.1016/j.ejpn.2012.04.007

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  18 in total

Review 1.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

2.  Dynamic changes of depolarizing GABA in a computational model of epileptogenic brain: Insight for Dravet syndrome.

Authors:  P Kurbatova; F Wendling; A Kaminska; A Rosati; R Nabbout; R Guerrini; O Dulac; G Pons; C Cornu; P Nony; C Chiron; P Benquet
Journal:  Exp Neurol       Date:  2016-05-28       Impact factor: 5.330

3.  Stiripentol for dravet syndrome: is it worth it?

Authors:  Eric Kossoff
Journal:  Epilepsy Curr       Date:  2014-01       Impact factor: 7.500

4.  Interneuron Desynchronization Precedes Seizures in a Mouse Model of Dravet Syndrome.

Authors:  Conny H Tran; Michael Vaiana; Johan Nakuci; Ala Somarowthu; Kevin M Goff; Nitsan Goldstein; Priya Murthy; Sarah F Muldoon; Ethan M Goldberg
Journal:  J Neurosci       Date:  2020-02-26       Impact factor: 6.167

Review 5.  Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies.

Authors:  Julia Oyrer; Snezana Maljevic; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou; Christopher A Reid
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

Review 6.  Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.

Authors:  An-Sofie Schoonjans; Lieven Lagae; Berten Ceulemans
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 7.  Epilepsy and brain channelopathies from infancy to adulthood.

Authors:  Emanuele Bartolini; Roberto Campostrini; Lorenzo Kiferle; Silvia Pradella; Eleonora Rosati; Krishna Chinthapalli; Pasquale Palumbo
Journal:  Neurol Sci       Date:  2019-12-14       Impact factor: 3.307

8.  A Transient Developmental Window of Fast-Spiking Interneuron Dysfunction in a Mouse Model of Dravet Syndrome.

Authors:  Morgana Favero; Nathaniel P Sotuyo; Emily Lopez; Jennifer A Kearney; Ethan M Goldberg
Journal:  J Neurosci       Date:  2018-08-13       Impact factor: 6.167

9.  Dravet syndrome and Dravet syndrome-like phenotype: a systematic review of the SCN1A and PCDH19 variants.

Authors:  Ana Carla Mondek Rampazzo; Rafael Rodrigues Pinheiro Dos Santos; Fernando Arfux Maluf; Renata Faria Simm; Fernando Augusto Lima Marson; Manoela Marques Ortega; Paulo Henrique Pires de Aguiar
Journal:  Neurogenetics       Date:  2021-05-03       Impact factor: 2.660

10.  Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine.

Authors:  Yifan Zhang; Angéla Kecskés; Daniëlle Copmans; Mélanie Langlois; Alexander D Crawford; Berten Ceulemans; Lieven Lagae; Peter A M de Witte; Camila V Esguerra
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.